Download PDF
Semin intervent Radiol 2022; 39(04): 400-405
DOI: 10.1055/s-0042-1758078
Review Article

Drug-Eluting Stents

Chetan Velagapudi
1   Department of Vascular and Interventional Radiology, Rush University Medical Center, Chicago, Illinois
,
Sreekumar Madassery
1   Department of Vascular and Interventional Radiology, Rush University Medical Center, Chicago, Illinois
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Endovascular revascularization strategies have advanced tremendously over the years and are now often considered first line for treatment of peripheral arterial disease. Drug-eluting stents (DESs) have been developed as one of the tools to overcome the limitations of elastic recoil and neointimal hyperplasia observed with balloon angioplasty and bare metal stents. While these stents have been extremely successful in coronary revascularization, they have not translated as effectively to the peripheral arteries which differ in their unique mechanical environments and differences in vessel and lesion composition. DESs, through their embedded pharmaceutical agent, seek to inhibit vascular smooth muscle cell (VSMC) proliferation and migration. Paclitaxel, sirolimus, and its derivatives (-limus family) achieve VSMC inhibition through unique mechanisms. Several clinical trials have been performed to evaluate the use of DES in the femoropopliteal and infrapopliteal territory and have demonstrated overall decrease in revascularization rates and improved clinical outcomes.

Keywords

interventional radiology - stents - drug-eluting stents - arterial - venous


Publication History

Article published online:
17 November 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Murray CJ, Barber RM, Foreman KJ. et al; GBD 2013 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet 2015; 386 (10009): 2145-2191
    CrossrefPubMedGoogle Scholar
  • 2 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 (Suppl S): S5-S67
    CrossrefPubMedGoogle Scholar
  • 3 Abu Dabrh AM, Steffen MW, Undavalli C. et al. The natural history of untreated severe or critical limb ischemia. J Vasc Surg 2015; 62 (06) 1642-51 .e3
    CrossrefPubMedGoogle Scholar
  • 4 Katib N, Thomas SD, Lennox AF, Yang JL, Varcoe RL. An endovascular- first approach to the treatment of critical limb ischemia results in superior limb salvage rates. J Endovasc Ther 2015; 22 (04) 473-481
    CrossrefPubMedGoogle Scholar
  • 5 Ellis SG, Stone GW, Cox DA. et al; TAXUS IV Investigators. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv 2009; 2 (12) 1248-1259
    CrossrefPubMedGoogle Scholar
  • 6 Davaine JM, Quillard T, Chatelais M. et al. Bone like arterial calcification in femoral atherosclerotic lesions: prevalence and role of osteoprotegerin and pericytes. Eur J Vasc Endovasc Surg 2016; 51 (02) 259-267
    CrossrefPubMedGoogle Scholar
  • 7 Matsuo Y, Takumi T, Mathew V. et al. Plaque characteristics and arterial remodeling in coronary and peripheral arterial systems. Atherosclerosis 2012; 223 (02) 365-371
    CrossrefPubMedGoogle Scholar
  • 8 Zacharias SK, Safian RD, Madder RD. et al. Invasive evaluation of plaque morphology of symptomatic superficial femoral artery stenoses using combined near-infrared spectroscopy and intravascular ultrasound. Vasc Med 2016; 21 (04) 337-344
    CrossrefPubMedGoogle Scholar
  • 9 Laird JR. Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries. J Endovasc Ther 2006; 13 (Suppl 2): II30-II40
    CrossrefPubMedGoogle Scholar
  • 10 Fischer GM, Llaurado JG. Collagen and elastin content in canine arteries selected from functionally different vascular beds. Circ Res 1966; 19 (02) 394-399
    CrossrefPubMedGoogle Scholar
  • 11 Iida O, Uematsu M, Soga Y. et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv 2011; 78 (04) 611-617
    CrossrefPubMedGoogle Scholar
  • 12 Bishop PD, Feiten LE, Ouriel K. et al. Arterial calcification increases in distal arteries in patients with peripheral arterial disease. Ann Vasc Surg 2008; 22 (06) 799-805
    CrossrefPubMedGoogle Scholar
  • 13 Narula N, Dannenberg AJ, Olin JW. et al. Pathology of peripheral artery disease in patients with critical limb ischemia. J Am Coll Cardiol 2018; 72 (18) 2152-2163
    CrossrefPubMedGoogle Scholar
  • 14 Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol 2000; 190 (03) 300-309
    CrossrefPubMedGoogle Scholar
  • 15 Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 2001; 104 (05) 600-605
    CrossrefPubMedGoogle Scholar
  • 16 Braun-Dullaeus RC, Mann MJ, Sedding DG, Sherwood SW, von der Leyen HE, Dzau VJ. Cell cycle-dependent regulation of smooth muscle cell activation. Arterioscler Thromb Vasc Biol 2004; 24 (05) 845-850
    CrossrefPubMedGoogle Scholar
  • 17 Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003; 3 (03) 193-203
    CrossrefPubMedGoogle Scholar
  • 18 Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000; 88 (11) 2619-2628
    CrossrefPubMedGoogle Scholar
  • 19 Axel DI, Kunert W, Göggelmann C. et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96 (02) 636-645
    CrossrefPubMedGoogle Scholar
  • 20 Tanner FC, Boehm M, Akyürek LM. et al. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation 2000; 101 (17) 2022-2025
    CrossrefPubMedGoogle Scholar
  • 21 Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001; 104 (08) 852-855
    CrossrefPubMedGoogle Scholar
  • 22 Schömig A, Dibra A, Windecker S. et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50 (14) 1373-1380
    CrossrefPubMedGoogle Scholar
  • 23 Xue L, Sharma R, Cochran K. Effects of rapamycin derivative ABT-578 on canine smooth muscle cells and endothelial cell proliferation. Preclinica 2004; 2: 451-455
    PubMedGoogle Scholar
  • 24 Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf 2015; 14 (07) 1055-1070
    CrossrefPubMedGoogle Scholar
  • 25 Schwartz SM. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 1997; 100 (11, Suppl): S87-S89
    PubMedGoogle Scholar
  • 26 Levin AD, Vukmirovic N, Hwang C-W, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A 2004; 101 (25) 9463-9467
    CrossrefPubMedGoogle Scholar
  • 27 Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2018; 7 (24) e011245
    CrossrefPubMedGoogle Scholar
  • 28 Farb A, Malone M, Maisel WH. Drug-coated devices for peripheral arterial disease. N Engl J Med 2021; 384 (02) 99-101
    CrossrefPubMedGoogle Scholar
  • 29 Secemsky EA, Kundi H, Weinberg I. et al. Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol 2019; 4 (04) 332-340
    CrossrefPubMedGoogle Scholar
  • 30 Secemsky EA, Kundi H, Weinberg I. et al. Drug-eluting stent implantation and long-term survival following peripheral artery revascularization. J Am Coll Cardiol 2019; 73 (20) 2636-2638
    CrossrefPubMedGoogle Scholar
  • 31 Freisinger E, Koeppe J, Gerss J. et al. Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis. Eur Heart J 2020; 41 (38) 3732-3739
    CrossrefPubMedGoogle Scholar
  • 32 Behrendt CA, Sedrakyan A, Peters F. et al. Editor's choice - long term survival after femoropopliteal artery revascularisation with paclitaxel coated devices: a propensity score matched cohort analysis. Eur J Vasc Endovasc Surg 2020; 59 (04) 587-596
    CrossrefPubMedGoogle Scholar
  • 33 Schneider PA, Brodmann M, Mauri L. et al. Paclitaxel exposure: long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials. Catheter Cardiovasc Interv 2020; 96 (05) 1087-1099
    CrossrefPubMedGoogle Scholar
  • 34 Ouriel K, Adelman MA, Rosenfield K. et al. Safety of paclitaxel-coated balloon angioplasty for femoropopliteal peripheral artery disease. JACC Cardiovasc Interv 2019; 12 (24) 2515-2524
    CrossrefPubMedGoogle Scholar
  • 35 Dake MD, Ansel GM, Bosiers M. et al. Paclitaxel-coated Zilver PTX drug-eluting stent treatment does not result in increased long-term all-cause mortality compared to uncoated devices. Cardiovasc Intervent Radiol 2020; 43 (01) 8-19
    CrossrefPubMedGoogle Scholar
  • 36 Nordanstig J, James S, Andersson M. et al. Mortality with paclitaxel-coated devices in peripheral artery disease. N Engl J Med 2020; 383 (26) 2538-2546
    CrossrefPubMedGoogle Scholar
  • 37 Secemsky EA, Shen C, Schermerhorn M, Yeh RW. Longitudinal assessment of safety of femoropopliteal endovascular treatment with paclitaxel-coated devices among Medicare beneficiaries: the SAFE-PAD study. JAMA Intern Med 2021; 181 (08) 1071-1080
    CrossrefPubMedGoogle Scholar
  • 38 Duda SH, Bosiers M, Lammer J. et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006; 13 (06) 701-710
    CrossrefPubMedGoogle Scholar
  • 39 Dake MD, Scheinert D, Tepe G. et al; Zilver PTX Single-Arm Study Investigators. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther 2011; 18 (05) 613-623
    CrossrefPubMedGoogle Scholar
  • 40 Dake MD, Ansel GM, Jaff MR. et al; Zilver PTX Investigators. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation 2016; 133 (15) 1472-1483 , discussion 1483
    CrossrefPubMedGoogle Scholar
  • 41 Iida O, Takahara M, Soga Y. et al; ZEPHYR Investigators. 1-year results of the ZEPHYR registry (Zilver PTX for the femoral artery and proximal popliteal artery): predictors of restenosis. JACC Cardiovasc Interv 2015; 8 (08) 1105-1112
    CrossrefPubMedGoogle Scholar
  • 42 Ishihara T, Takahara M, Iida O. et al; ZEPHYR Investigators. Comparable 2-year restenosis rates following subintimal and intraluminal drug-eluting stent implantation for femoropopliteal chronic total occlusion. J Endovasc Ther 2016; 23 (06) 889-895
    CrossrefPubMedGoogle Scholar
  • 43 Zeller T, Dake MD, Tepe G. et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv 2013; 6 (03) 274-281
    CrossrefPubMedGoogle Scholar
  • 44 Müller-Hülsbeck S, Keirse K, Zeller T, Schroë H, Diaz-Cartelle J. Twelve-month results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease. J Endovasc Ther 2016; 23 (05) 701-707
    CrossrefPubMedGoogle Scholar
  • 45 Gasior P, Cheng Y, Valencia AF. et al. Impact of fluoropolymer- based paclitaxel delivery on neointimal proliferation and vascular healing: a comparative peripheral drug-eluting stent study in the familial hypercholesterolemic swine model of femoral restenosis. Circ Cardiovasc Interv 2017; 10 (05) 10
    CrossrefPubMedGoogle Scholar
  • 46 Müller-Hülsbeck S, Benko A, Soga Y. et al. Two-year efficacy and safety results from the IMPERIAL randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol 2021; 44 (03) 368-375
    CrossrefPubMedGoogle Scholar
  • 47 Graziani L, Silvestro A, Bertone V. et al. Vascular involvement in diabetic subjects with ischemic foot ulcer: a new morphologic categorization of disease severity. Eur J Vasc Endovasc Surg 2007; 33 (04) 453-460
    CrossrefPubMedGoogle Scholar
  • 48 Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg 2008; 47 (05) 975-981
    CrossrefPubMedGoogle Scholar
  • 49 Mustapha JA, Finton SM, Diaz-Sandoval LJ, Saab FA, Miller LE. Percutaneous transluminal angioplasty in patients with infrapopliteal arterial disease: systematic review and meta-analysis. Circ Cardiovasc Interv 2016; 9 (05) e003468
    CrossrefPubMedGoogle Scholar
  • 50 Spreen MI, Martens JM, Knippenberg B. et al. Long-term follow-up of the PADI trial: percutaneous transluminal angioplasty versus drug-eluting stents for infrapopliteal lesions in critical limb ischemia. J Am Heart Assoc 2017; 6 (04) e004877
    CrossrefPubMedGoogle Scholar
  • 51 Scheinert D, Katsanos K, Zeller T. et al; ACHILLES Investigators. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol 2012; 60 (22) 2290-2295
    CrossrefPubMedGoogle Scholar
  • 52 Rastan A, Brechtel K, Krankenberg H. et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol 2012; 60 (07) 587-591
    CrossrefPubMedGoogle Scholar
  • 53 Bosiers M, Scheinert D, Peeters P. et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg 2012; 55 (02) 390-398
    CrossrefPubMedGoogle Scholar
  • 54 Feiring AJ, Krahn M, Nelson L, Wesolowski A, Eastwood D, Szabo A. Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (PReventing Amputations using Drug eluting StEnts) trial. J Am Coll Cardiol 2010; 55 (15) 1580-1589
    CrossrefPubMedGoogle Scholar
  • 55 Adam DJ, Beard JD, Cleveland T. et al; BASIL Trial Participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005; 366 (9501): 1925-1934
    CrossrefPubMedGoogle Scholar
  • 56 Antoniou GA, Chalmers N, Kanesalingham K. et al. Meta-analysis of outcomes of endovascular treatment of infrapopliteal occlusive disease with drug-eluting stents. J Endovasc Ther 2013; 20 (02) 131-144
    CrossrefPubMedGoogle Scholar
  • 57 Fusaro M, Cassese S, Ndrepepa G. et al. Drug-eluting stents for revascularization of infrapopliteal arteries: updated meta-analysis of randomized trials. JACC Cardiovasc Interv 2013; 6 (12) 1284-1293
    CrossrefPubMedGoogle Scholar
  • 58 Katsanos K, Spiliopoulos S, Diamantopoulos A, Karnabatidis D, Sabharwal T, Siablis D. Systematic review of infrapopliteal drug-eluting stents: a meta-analysis of randomized controlled trials. Cardiovasc Intervent Radiol 2013; 36 (03) 645-658
    CrossrefPubMedGoogle Scholar
  • 59 Varcoe RL, Paravastu SC, Thomas SD, Bennett MH. The use of drug-eluting stents in infrapopliteal arteries: an updated systematic review and meta-analysis of randomized trials. Int Angiol 2019; 38 (02) 121-135
    CrossrefPubMedGoogle Scholar
  • 60 Zhang J, Xu X, Kong J. et al. Systematic review and meta-analysis of drug-eluting balloon and stent for infrapopliteal artery revascularization. Vasc Endovascular Surg 2017; 51 (02) 72-83
    CrossrefPubMedGoogle Scholar